・Vanda shares have rallied about 62% since mid-November, erasing the stock’s losses for the year amid a series of news flows. ・Tradipitant previously failed in gastroparesis but is now under FDA ...
Proposal Delivers Immediate, Compelling and Certain Cash Value for Vanda Shareholders with a Highly Attractive Premium of 80% to Vanda’s Closing Share Price on October 11, 2024 Urges Vanda ...
D.C.-based Vanda Pharmaceuticals, with treatments in development for jet lag, sea sickness and stage fright, has received an unsolicited takeover offer from British drugmaker Cycle Pharmaceuticals in ...
WASHINGTON, May 24, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Company's Board of Directors (the "Board") carefully reviewed the revised ...
In recent months, Vanda Pharmaceuticals has been busy working to grow its commercial presence through its acquisition of Johnson & Johnson's Ponvory and its recent bipolar disorder approval for Fanapt ...
After years of back-and-forth with the FDA over Hetlioz's potential use as a jet lag disorder treatment, Vanda Pharmaceuticals is pursuing a new route to establish the drug in the space. Hetlioz was ...
WASHINGTON, Feb. 20, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets, a ...
Good afternoon, and welcome to the Quarter One 2025 Vanda Pharmaceuticals Incorporated Earnings Conference Call. I am Franz, and I will be the operator assisting you today. All lines have been placed ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results